Subtype
Colorectal Adenocarcinoma
CI-CAN-00005002Explore in graph →
114 active trials1 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005002Explore in graph →
Clinical trials
367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (54)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06908031 | SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT) | completed | Phase 2 | 49 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER |
| 1 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT05480306 | Phase 2 Study of DKN-01 in Colorectal Cancer(DeFianCe) | completed | Phase 2 | 188 | Leap Therapeutics, Inc.INDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03642067 | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | completed | Phase 2 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04554836 | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | completed | Phase 2 | 6 | TheraOpOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | completed | Phase 2 | 117 | Seagen Inc.INDUSTRY | 5 | Nov 26, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03800602 | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | completed | Phase 2 | 29 | Emory UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT03206073 | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02641691 | Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum(NORMAL-R) | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01674309 | First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | completed | Phase 2 | 65 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00321685 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01703910 | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic | completed | Phase 2 | 29 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00032110 | Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 31, 2015 | clinicaltrials |
| NCT01554059 | Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients(New Beat) | completed | Phase 2 | 25 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00942266 | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 58 | Roswell Park Cancer InstituteOTHER | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00026234 | Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT00005818 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006094 | Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00597506 | Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus(BEV/EV) | completed | Phase 2 | 50 | Herbert HurwitzOTHER | 1 | Dec 27, 2012 | clinicaltrials |
| NCT00165217 | Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials